Ensysce Biosciences, Inc.
LA JOLLA, CA · CIK 0001716947 · Biotech · Public
Tamper-resistant opioid formulations with abuse-deterrent technology
ensysce.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $103M
- 8 Form D · Aug 2026
- 1 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 26
- 3 granted · 23 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2021202220232024202520262027
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $5,300,000 | |
| Private capital raised | Form D · SEC | $4,240,000 | |
| Private capital raised | Form D · SEC | $2,816,073 | |
| Private capital raised | Form D · SEC | $4,718,295 | |
| Private capital raised | Form D · SEC | $5,055,648 | |
| Private capital raised | Form D · SEC | $1,100,000 | |
| Private capital raised | Form D · SEC | $2,200,012 | |
| Private capital raised | Form D · SEC | $77,200,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2279 | CURAVAC, INC. | — | $4.7M |
| 2280 | bluebird bio | — | $179M |
| 2281 | EFFECTORBIO, INC. | — | — |
| 2282 | Ensysce Biosciences, Inc. | — | $103M |
| 2283 | VIACYTE, INC. | — | $150M |
| 2284 | EMULATE THERAPEUTICS, INC. | — | $12M |
| 2285 | Dicerna Pharmaceuticals, Inc. | — | $90M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Andrew BentonDirector
- William ChangDirector
- Bob GowerDirector
- David HumphreyExecutive Officer
- D KirkpatrickDirector · Executive Officer
- Adam LevinDirector
- Steve MartinDirector
- Lee RauchDirector
- Curtis RosebraughDirector
Patents
- Compositions Comprising Enzyme-cleavable Prodrugs And Controlled Release Nafamostat And Methods Of Use Thereofapplication
- Modified Release Compositions Of Nafamostat And Methods Of Using Samegranted
- Compositions Comprising Enzyme-cleavable Prodrugs And Controlled Release Nafamostat And Methods Of Use Thereofgranted
- Enzyme-cleavable Methadone Prodrugs And Methods Of Use Thereofapplication
- Enzyme-cleavable Methadone Prodrugs And Methods Of Use Thereofgranted
- Methods For Treating Viral Infections With Nafamostatapplication
- Compositions Comprising Enzyme-cleavable Amphetamine Prodrugs And Inhibitors Thereofapplication
- Single Walled Carbon Nanotube Polynucleotide Complexes and Methods Related Theretoapplication
- Single Walled Carbon Nanotube Polynucleotide Complexes and Methods Related Theretoapplication
- Methadone Active Agents And Methods Of Use Thereofapplication
- Modified Release Compositions Of Nafamostat And Methods Of Using Sameapplication
- Methadone Active Agents And Methods Of Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.